BackSpectrum Pharmaceuticals Overview

Spectrum Pharmaceuticals EBIT

Spectrum Pharmaceuticals's EBIT is $-64M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$4.87M
↑ 65.37% YoY

As of Mar 31, 2023

Annual EBIT (TTM)

-$63.50M
↑ 50.42% YoY

Trailing 12 months ending Mar 31, 2023

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Spectrum Pharmaceuticals (SPPI) FAQ

The latest EBIT for SPPI is $-64M as of March 2023. That compares with $-130M in the prior-year period — up 50.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Spectrum Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPPI's EBIT moved from $-130M to $-64M — a 50.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Spectrum Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, SPPI currently prints $-64M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Spectrum Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-64M for SPPI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting SPPI's EBIT ($-64M), review year-over-year change from $-130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.